International Angelman Day is Feb. 15 and, around the world, about 50 organizations and scores of supporters will come…
Mary Chapman
Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. She’s won a Society of Professional Journalists award for outstanding reporting.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Mary Chapman
Angelman syndrome families in the United Kingdom may now request financial support for items — like tablets or adaptive…
After the pandemic resulted in last year’s fundraiser being an online experience, the Foundation for Angelman Syndrome Therapeutics (FAST)…
Families of Angelman syndrome (AS) patients in the U.K. have a new resource to help pay for items they…
The inaugural meeting of the International Angelman Syndrome Research Council, known as INSYNC-AS, focused on the translational research landscape in…
At its first virtual investor event, biotech company Centogene set a bold mission: to cure 100 rare diseases…
To help patient advocacy leaders and their partners better understand how global health statistics codes — known as ICD codes…
Those who wish to gain practical tools for living optimally with rare diseases are encouraged to attend the annual…
Philanthropists Ryan and Annie Jacob have pledged up to $250,000 to the Foundation for Angelman Syndrome Therapeutics, known as…
The Foundation for Angelman Syndrome Therapeutics, known as FAST, will get a high-octane boost when professional racecar driver Cameron…